MAPT and dementia: Different clinical, fluid, and imaging biomarkers of AD severity were found to be associated with progressive tau deposition in subsequent Braak stages or a stronger signal in Braak ROIs: cognitive decline (11,17,22–24,26,27,33), dementia severity (17,26), amyloid positivity or load (11,17–19,22–24,26), CSF measures (22,26), plasma phosphorylated tau (26), diminished hippocampal volume (11,17,18,23), and cortical atrophy (31).